The Latest Breaking News from Finch

I Turned Cleaning Into a Game for My Neurodivergent Mind – I Was Amazed at How Easy it Made Boring Chores

Who said games are just for children?

Homes & Gardens · Jan 12

My life’s a mess. Will turning it into a game make everything better?

With two small kids and a dog to take care of, I often struggle to look after myself. Self-care apps promise to help – if you can handle the quests, magic potions and rainbow stones. I put four of them to the test

The Guardian - UK · Apr 27, 2025

Popular Glasgow restaurant to 'temporarily close' its doors

A POPULAR Glasgow restaurant is set to 'temporarily close' its doors for a huge makeover...

The National (Scotland) · Sep 16, 2024

September 2022 appointments and promotions from across the East Midlands

Latest East Midlands appointments include a refugee from war-torn Ukraine

Birmingham Post · Sep 23, 2022

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Benzinga · Aug 26, 2022

U.S. FDA removes Clinical Hold on Finch's investigational new drug (IND) application for CP101

The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in  the prevention of recurrent C. difficile infection (CDI).

Benzinga · Apr 28, 2022

Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs

Finch Therapeutics Group Inc (NASDAQ:FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees. The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold…

Benzinga · Apr 20, 2022

See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ:FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI). The Company has paused enrollment in the trial as the FDA has asked for additional information about Finch's SARS-CoV-2 donor screening protocols. The FDA placed Finch's investigational new…

Benzinga · Mar 2, 2022

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Mar 2, 2022